"Avec une communauté de près de 16 000 professionnels, le CHU de Lille est l’un des plus grands campus santé du Nord de l’Europe. Hôpital universitaire de recours et de référence, d’enseignement, d’innovation et de recherche, il prend en charge des pathologies lourdes nécessitant un plateau médico-technique de pointe et une expertise médicale spécialisée. Près de 1.4 millions de patients y sont pris en charge chaque année, permettant au CHU de Lille de développer une expertise à la fois pour ses activités de recours et pour celles de proximité."

During the past decade, CHRU, Lille conducted 498 clinical trials. In the 10-year time frame, 498 clinical trials started and 65 clinical trials were completed, i.e. on average, 13.1% percent of trials that started reached the finish line to date. In the past 5 years, 246 clinical trials started and 50 clinical trials were completed. i.e. 20.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHRU, Lille" #1 sponsor was "University Hospital, Lille" with 36 trials, followed by "Nantes University Hospital" with 27 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 25 trials sponsored, "University Hospital, Brest" with 18 trials sponsored and "Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives" with 18 trials sponsored. Other sponsors include 585 different institutions and companies that sponsored additional 245 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHRU, Lille" #1 collaborator was "Ministry of Health, France" with 28 trials as a collaborator, "University Hospital, Lille" with 13 trials as a collaborator, "National Cancer Institute, France" with 9 trials as a collaborator, "Novartis" with 8 trials as a collaborator and "AstraZeneca" with 7 trials as a collaborator. Other collaborators include 407 different institutions and companies that were collaborators in the rest 310 trials.

According to Clinical.Site data, the most researched conditions in "CHRU, Lille" are "Multiple Myeloma" (20 trials), "Multiple Sclerosis" (16 trials), "Acute Myeloid Leukemia" (14 trials), "Crohn's Disease" (14 trials) and "Heart Failure" (10 trials). Many other conditions were trialed in "CHRU, Lille" in a lesser frequency.

Most popular intervention types in "CHRU, Lille" are "Drug" (325 trials), "Other" (121 trials), "Device" (114 trials), "Procedure" (76 trials) and "Biological" (46 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (56 trials), "Dexamethasone" (15 trials), "placebo" (10 trials), "Rituximab" (9 trials) and "radiation therapy" (8 trials). Other intervention names were less common.

The vast majority of trials in "CHRU, Lille" are 670 trials for "All" genders, 29 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are 273 active trials in "CHRU, Lille". 19 are not yet recruiting, 183 are recruiting, 67 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 305 completed trials in CHRU, Lille, undefined suspended trials, and 63 terminated clinical trials to date.

Out of the total trials that were conducted in CHRU, Lille, 37 "Phase 1" clinical trials were conducted, 138 "Phase 2" clinical trials and 178 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 41 trials, and there were also 157 trials that are defined as “Not Applicable".

CHRU, Lille has several departments that took part in Clinical trials: "Medical Intensive Care Unit" - 3 trials